These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36514034)

  • 21. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
    Tombal B; Saad F; Penson D; Hussain M; Sternberg CN; Morlock R; Ramaswamy K; Ivanescu C; Attard G
    Lancet Oncol; 2019 Apr; 20(4):556-569. PubMed ID: 30770294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors.
    Liao W; Xu H; Hutton D; Wu Q; Zhou K; Luo H; Lei W; Feng M; Yang Y; Wen F; Li Q
    Front Oncol; 2021; 11():692005. PubMed ID: 34938653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Monk BJ; Tewari KS; Dubot C; Caceres MV; Hasegawa K; Shapira-Frommer R; Salman P; Yañez E; Gümüş M; Hurtado de Mendoza MO; Samouëlian V; Castonguay V; Arkhipov A; Tekin C; Li K; Martin Nguyen A; Monberg MJ; Colombo N; Lorusso D
    Lancet Oncol; 2023 Apr; 24(4):392-402. PubMed ID: 36878237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma.
    Janku F; Bauer S; Shoumariyeh K; Jones RL; Spreafico A; Jennings J; Psoinos C; Meade J; Ruiz-Soto R; Chi P
    ESMO Open; 2022 Aug; 7(4):100520. PubMed ID: 35753087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
    Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
    Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
    Motzer R; Porta C; Alekseev B; Rha SY; Choueiri TK; Mendez-Vidal MJ; Hong SH; Kapoor A; Goh JC; Eto M; Bennett L; Wang J; Pan JJ; Saretsky TL; Perini RF; He CS; Mody K; Cella D
    Lancet Oncol; 2022 Jun; 23(6):768-780. PubMed ID: 35489363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
    Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
    Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
    Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study.
    Li J; Cai S; Zhou Y; Zhang J; Zhou Y; Cao H; Wu X; Deng Y; Huang Z; Dong J; Shen L
    Clin Cancer Res; 2022 Aug; 28(16):3425-3432. PubMed ID: 35686969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE).
    Necchi A; Nishiyama H; Matsubara N; Lee JL; Petrylak DP; de Wit R; Drakaki A; Liepa AM; Mao H; Bell-McGuinn K; Powles T
    BMC Urol; 2020 Nov; 20(1):181. PubMed ID: 33160359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma.
    Choueiri TK; Tomczak P; Park SH; Venugopal B; Symeonides S; Hajek J; Ferguson T; Chang YH; Lee JL; Haas N; Sawrycki P; Sarwar N; Gross-Goupil M; Thiery-Vuillemin A; Mahave M; Kimura G; Perini RF; Saretsky TL; Bhattacharya R; Xu L; Powles T
    Oncologist; 2024 Feb; 29(2):142-150. PubMed ID: 37589219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China.
    Li J; Zhang J; Zhang Y; Qiu H; Zhou Y; Zhou Y; Zhang X; Zhou Y; Zhu Y; Li Y; Wang M; Shen K; Tao K; Wu X; Wang H; Zhang B; Ling J; Ye Y; Wu X; Qu H; Ma Y; Jiao X; Zheng H; Jin J; Liu Z; Tan M; Fang Y; Zhang P; Zhang N; Lei C; Cai Z; Liang B; Peng Z; Huang Z; Dong J; Shen L
    Eur J Cancer; 2024 Jan; 196():113439. PubMed ID: 37980854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.
    Elsawy M; Chavez JC; Avivi I; Larouche JF; Wannesson L; Cwynarski K; Osman K; Davison K; Rudzki JD; Dahiya S; Dorritie K; Jaglowski S; Radford J; Morschhauser F; Cunningham D; Martin Garcia-Sancho A; Tzachanis D; Ulrickson ML; Karmali R; Kekre N; Thieblemont C; Enblad G; Dreger P; Malladi R; Joshi N; Wang WJ; Solem CT; Snider JT; Cheng P; To C; Kersten MJ
    Blood; 2022 Nov; 140(21):2248-2260. PubMed ID: 35839452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study.
    Raimondi A; Di Maio M; Morano F; Corallo S; Lonardi S; Antoniotti C; Rimassa L; Sartore-Bianchi A; Tampellini M; Ritorto G; Murialdo R; Clavarezza M; Zaniboni A; Adamo V; Tomasello G; Petrelli F; Antonuzzo L; Giordano M; Cinieri S; Longarini R; Bergamo F; Niger M; Antista M; Peverelli G; de Braud F; Di Bartolomeo M; Pietrantonio F
    Eur J Cancer; 2020 Aug; 135():230-239. PubMed ID: 32623288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma.
    Al-Batran SE; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov ON; Kim TY; Cunningham D; Rougier P; Muro K; Liepa AM; Chandrawansa K; Emig M; Ohtsu A; Wilke H
    Ann Oncol; 2016 Apr; 27(4):673-9. PubMed ID: 26747859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Comparative Study Evaluating the Quality of Life and Survival Outcomes in Patients Receiving Chemotherapy Versus Oral Tyrosine Kinase Inhibitor in the Third Line and Beyond Setting for Advanced NSCLC.
    Noronha V; Menon NS; Patil VM; Chandrakanth MV; More S; Dhanawat A; Chowdhary OR; Singh AC; Goud S; Shah S; Karuvandan N; Jobanputra KN; Shah DK; Shah MJ; Sarma R; Patel D; Joarder R; Kumar P; John A; Kaur J; Bagra S; Purandare N; Janu A; Mahajan A; Prabhash K
    JTO Clin Res Rep; 2024 Jan; 5(1):100622. PubMed ID: 38292414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT).
    Yoo C; Ryu MH; Nam BH; Ryoo BY; Demetri GD; Kang YK
    Eur J Cancer; 2016 Jan; 52():201-8. PubMed ID: 26699729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
    Oza AM; Matulonis UA; Malander S; Hudgens S; Sehouli J; Del Campo JM; Berton-Rigaud D; Banerjee S; Scambia G; Berek JS; Lund B; Tinker AV; Hilpert F; Vázquez IP; D'Hondt V; Benigno B; Provencher D; Buscema J; Agarwal S; Mirza MR
    Lancet Oncol; 2018 Aug; 19(8):1117-1125. PubMed ID: 30026000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.